145841-10-7
|
|
|
- CAS号:
- 145841-10-7
- 英文名:
- Sch-42495 (racemate)
- 英文别名:
- Sch-42495 (racemate);L-Methionine, N-[2-[(acetylthio)methyl]-3-(2-methylphenyl)-1-oxopropyl]-, ethyl ester
- 中文名:
- 145841-10-7
- 中文别名:
- 化合物 T12866;化合物 SCH 42495 RACEMATE
- CBNumber:
- CB33175586
- 分子式:
- C20H29NO4S2
- 分子量:
- 411.58
- MOL File:
- 145841-10-7.mol
|
|
|
145841-10-7化学性质
-
沸点:
-
597.3±50.0 °C(Predicted)
-
|
-
密度:
-
1.158±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
酸度系数(pKa):
-
13.50±0.46(Predicted)
-
|
145841-10-7性质、用途与生产工艺
SCH 42495 racemate 是 Sch-42495 的外消旋体。SCH 42495 是一种具有口服活性的中性金属内肽酶 (NEP) 抑制剂，具有抗高血压活性。SCH 42495 是 SCH 42354 的口服活性前药。
SCH 42495 selectively inhibits hydrolysis of leu-enkephalin and ANF (IC
50
of 8.3 and 10.0 nM, respectively) in vitro.
SCH 42495 (30 mg/kg; oral gavage; twice daily) causes a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy in hypoxic rats after 10 days.
Treatment with SCH 42495 (30 mg/kg; oral gavage; twice daily) leads to a decrease in cardiovascular remodelling secondary to chronic hypoxia in rats.
SCH 42495 (oral doses of 1, 3, or 10 mg/kg) produces significant reductions in blood pressure in DOCA-N a hypertensive rats of 22±6, 43±7, and 62±12 mm Hg, respectively.
|
Animal Model:
|
Hypoxic rats
|
|
Dosage:
|
30 mg/kg
|
|
Administration:
|
Oral gavage; twice daily for 10 days
|
|
Result:
|
Caused a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy.
Led to a decrease in cardiovascular remodelling secondary to chronic hypoxia.
|
145841-10-7
上下游产品信息
上游原料
下游产品
145841-10-7, 145841-10-7 相关搜索:
- 抑制剂
- 化合物 SCH 42495 RACEMATE
- 化合物 T12866
- 145841-10-7
- L-Methionine, N-[2-[(acetylthio)methyl]-3-(2-methylphenyl)-1-oxopropyl]-, ethyl ester
- Sch-42495 (racemate)